The Novo Nordisk Foundation Controls the Votes. So It Controls Who Runs the Company.

On May 16, 2025, Novo Nordisk announced that CEO Lars Fruergaard Jørgensen would step down. He would stay on during the search for his replacement to ensure a smooth transition. The stock had lost more than 50% of its value since mid-2024.

Read the exact language from the announcement: "The Novo Nordisk Foundation Board initiated a dialogue with the Novo Nordisk Board on the merits of an accelerated CEO succession."

Not suggested. Initiated a dialogue. Expressed a wish.

The Foundation holds the voting control through its investment company, Novo Holdings A/S. It controls the majority of votes at every shareholder meeting. When an entity with that much power initiates dialogue about succession, the outcome is decided before the board votes.

Jørgensen had tripled sales, profits, and share price in eight years. None of that mattered once the Foundation decided the moment to move on had come.

In connection with the change, Lars Rebien Sørensen, chair of the Foundation, would join the Novo Nordisk Board as an observer, with plans for formal nomination in 2026. A Foundation executive watching board meetings, then moving to a board seat, is tightening the link between the entity that owns votes and the entity that spends them.

What I would look for: whether Rebien Sørensen gets a committee seat or becomes ceremonial. Whether the new CEO is someone the Foundation already knows. Whether the company's strategy actually changes or just the messenger does.

The bigger lesson is that a CEO serves at the pleasure of whoever holds the votes. Extraordinary results do not protect you if the shareholder decides the structure needs a different leader. A board that answers to an owner with 50% voting power is not really making a free choice.